These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8202964)
21. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Langworth S; Bodlund O; Agren H J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139 [TBL] [Abstract][Full Text] [Related]
22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074 [TBL] [Abstract][Full Text] [Related]
24. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Roose SP; Sackeim HA; Krishnan KR; Pollock BG; Alexopoulos G; Lavretsky H; Katz IR; Hakkarainen H; Am J Psychiatry; 2004 Nov; 161(11):2050-9. PubMed ID: 15514406 [TBL] [Abstract][Full Text] [Related]
25. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Bech P; Tanghøj P; Andersen HF; Overø K Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396 [TBL] [Abstract][Full Text] [Related]
26. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312 [TBL] [Abstract][Full Text] [Related]
27. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. Benedetti F; Colombo C; Pontiggia A; Bernasconi A; Florita M; Smeraldi E J Clin Psychiatry; 2003 Jun; 64(6):648-53. PubMed ID: 12823078 [TBL] [Abstract][Full Text] [Related]
28. Paroxetine versus placebo: a double-blind comparison in depressed patients. Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471 [TBL] [Abstract][Full Text] [Related]
29. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Robert P; Montgomery SA Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():29-35. PubMed ID: 7622809 [TBL] [Abstract][Full Text] [Related]
31. Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo. Zilcha-Mano S; Roose SP; Brown PJ; Rutherford BR Am J Geriatr Psychiatry; 2017 Jun; 25(6):654-661. PubMed ID: 28318797 [TBL] [Abstract][Full Text] [Related]
32. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Vartiainen H; Tiihonen J; Putkonen A; Koponen H; Virkkunen M; Hakola P; Lehto H Acta Psychiatr Scand; 1995 May; 91(5):348-51. PubMed ID: 7639092 [TBL] [Abstract][Full Text] [Related]
33. Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke. Simis S; Nitrini R Arq Neuropsiquiatr; 2006 Jun; 64(2B):412-7. PubMed ID: 16917611 [TBL] [Abstract][Full Text] [Related]
35. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Bould H; Wiles N; Potokar J; Cowen P; Nutt DJ; Peters TJ; Lewis G J Psychopharmacol; 2012 May; 26(5):663-9. PubMed ID: 22223618 [TBL] [Abstract][Full Text] [Related]
36. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G; JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876 [TBL] [Abstract][Full Text] [Related]
37. Effıcacy of cıtalopram on stroke recurrence: A randomızed clınıcal trıal. Ece Çetin F; Kumral E; Saffet Gönül A; Nezih Özdemir H; Orman M J Clin Neurosci; 2022 Jul; 101():168-174. PubMed ID: 35597066 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Savadi Oskouie D; Sharifipour E; Sadeghi Bazargani H; Hashemilar M; Nikanfar M; Ghazanfari Amlashi S; Abbaszade Z; Sadeghihokmabadi E; Rikhtegar R; Golzari SEJ Neurorehabil Neural Repair; 2017 Jul; 31(7):638-647. PubMed ID: 28454498 [TBL] [Abstract][Full Text] [Related]
39. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Lavretsky H; Reinlieb M; St Cyr N; Siddarth P; Ercoli LM; Senturk D Am J Psychiatry; 2015 Jun; 172(6):561-9. PubMed ID: 25677354 [TBL] [Abstract][Full Text] [Related]
40. A retrospective study of citalopram in adolescents with depression. Bostic JQ; Prince J; Brown K; Place S J Child Adolesc Psychopharmacol; 2001; 11(2):159-66. PubMed ID: 11436955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]